Scientists at The University of Texas Health Science Center at Houston (UTHealth) report that fat cells support the progression of prostate cancer and could be a key target in new treatments. Findings of their preclinical study appeared in the journal Oncogene.
The prostate is a male reproductive organ and prostate cancer develops mainly in older men and in African-American men.
“Our results demonstrate that interaction with cells of fat tissue makes cancer cells more migratory and more resistant to chemotherapy,” said Mikhail Kolonin, PhD, the study’s senior author and director of the Center for Metabolic and Degenerative Diseases at McGovern Medical School at UTHealth.
Kolonin’s research focused on stem cells of fat tissue (adipose stromal cells). Previously his group discovered that these cells support tumor-nourishing blood vessels. Their new study investigated how prostate tumors use adipose stromal cells to invade surrounding tissues and fight off popular prostate cancer medications such as docetaxel, cabazitaxel, and cisplatin.
Kolonin and colleagues conducted experiments with cultured human cells and with mouse models of obesity-associated prostate cancer. They used an experimental drug called D-CAN that they had previously developed that kills adipose stromal cells. “The prostate cancer was significantly less resistant to chemotherapy upon D-CAN treatment,” Kolonin said.
“Our data, demonstrating that adipose stromal cell depletion enhances chemotherapy at a non-toxic dose in mouse models, may pave the way to combination therapies with lower side effects and improved anti-cancer efficacy,” the researchers report.
About 6 in 10 cases of prostate cancer are diagnosed in men aged 65 or older, and the disease is rare before age 40, according to the American Cancer Society. The average age at the time of diagnosis is 66.
Kolonin’s collaborators include first author Fei Su, PhD, of UTHealth; and Songyeon Ahn; Achinto Saha, PhD; and John DiGiovanni, PhD, of the Dell Pediatric Research Institute at the University of Texas at Austin.
The study, titled “Adipose stromal cell targeting suppresses prostate cancer epithelial mesenchymal transition and chemoresistance,” was supported by the National Institutes of Health grants (R21 CA216745, R01 CA196259) and the Harry E. Bovay, Jr. Foundation.
Kolonin’s laboratory is in the Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases at UTHealth.
Kolonin is the Harry E. Bovay, Jr. Distinguished University Chair in Metabolic Disease Research at McGovern Medical School. He is also on the faculty of The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences.
Vietnam Veteran receives replacement medals https://t.co/aMTfLrP5WS via @theindependent
RT @UTPhysicians: UTHealthCares, a student-led initiative to help the community, is holding their 2nd annual health fair on Saturday, Jan.…
RT @UTPhysicians: A well-woman exam is an important way to stay healthy. The main goals are to document/update your health habits and histo…
RT @UTPhysicians: Falling can lead to broken bones or disability, and each year 1 in 4 older adults are injured due to falls. To help lower…
Department of Veterans Affairs making suicide prevention a top clinical priority https://t.co/vhFQwYkMYv @WDTnews
Veterans Crisis Line call centers, where qualified, caring responders answer the calls of Veterans, Service members, and their families and friends in times of crisis https://t.co/vzoTcpuBMs #BeThere
@spiderwalshy Not at this time, but through clinical trials our researchers are exploring new uses for immunotherapy with the hope that we’ll be able to use it to treat more cancers, such as pancreatic cancer.
RT @SurvivorNetTeam: If you're considering getting genetic testing to assess your #cancerrisk, there are some things you should know before…
Because immunotherapy trains the immune system to attack cancer, rather than attacking cancer directly, immunotherapy’s side effects may differ from those of others types of cancer treatment.Here’s what our experts want patients to know. @viveksubbiah @vanmorrisMD #endcancer https://t.co/wGd40rhzTq
We were honored to host The Rev. Dr. Derek. Barber King, Sr., nephew of Dr. Martin Luther King, Jr., to celebrate the life & legacy of Dr. King.Dr. King’s unwavering focus & passion will forever be an inspiration on our path forward. #MLKDay https://t.co/HimY0WY4fP
According to the American Cancer Society, obesity acts as a risk factor in developing liver, pancreatic and endometrial cancers. Here are simple exercises to sit less and move more: https://t.co/XtYhfqN2RV.
Join us for a twitter chat on Jan. 23 at 2 p.m. CST (3 p.m. ET) to discuss what you can do to have a healthy baby. #Best4YouBest4Baby #WellnessWed https://t.co/CGMqI4SmMK
CHI St. Luke's Health@CHI_StLukes
.@tdouglaslawson, President of Baylor St. Luke's Medical Center & CEO of the CHI Texas Division, led a moving ceremony with Minister Howard Watson and Reverend D. Darnell to celebrate the vital work and lasting national impact of Dr. King. https://t.co/3hAiyGJzww
CHI St. Luke's Health@CHI_StLukes
Facilities across the CHI Texas Division are honoring the life and legacy of Dr. Martin Luther King, Jr. today. We are proud to be an organization committed to social justice, diversity, and respect for pioneers in equality like Dr. King. #MLKday
Stargazers flocked to watch the #SuperBloodWolfMoon at a public viewing hosted by the Rice University Campus Observatory.The lunar eclipse began around 9:30 p.m. Sunday and ended around 12:50 a.m. https://t.co/kIb4QKP3Nz